The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease

• DOI: 10.14814/phy2.14556
• Publication Date: 2020-09-05T15:45:16Z
• Authors: Natsumi Tomita; Yuji Hotta; Aya Naiki‐Ito; Kana Hirano; Tomoya Kataoka; Yasuhiro Maeda; Satoru Takahashi; Kazunori Kimura
• Keywords: Glomerulosclerosis

Phosphodiesterase 5 inhibitors are widely used to treat erectile dysfunction and lower urinary tract symptoms with benign prostatic hyperplasia. Recent studies have indicated the renoprotective effects of this class compounds. Whether renoprotection depends on blood pressure reduction remains controversial. In study, we investigated phosphodiesterase inhibitor, tadalafil, in a rat model high-salt induced kidney injury hypertension. Dahl salt-sensitive rats were fed normal diet, (8% sodium chloride) or diet oral administration either low- high-dose tadalafil (1 10 mg kg-1 day-1 , respectively). Serum creatinine, protein, measured at baseline after 8 weeks, which point examined for glomerular fibrosis. PAI1 mRNA levels also evaluated. After pressure, serum protein significantly higher group than those normal-salt group. creatinine both groups group, while only affected pressure. addition, glomerulosclerosis α-smooth muscle actin expression decreased treatment groups. increased but tadalafil-treated Our results that prevented fibrosis chronic disease model. Mechanistically, these may be associated structure protection.